NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 5, 2 ...

Core Viewpoint - Zenas BioPharma, Inc. is under investigation for potential securities fraud following disappointing results from a clinical trial, which led to significant stock price declines [1][2][3]. Group 1: Company Overview - Zenas BioPharma, Inc. trades on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [2]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas, but analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [2]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [2]. - On a subsequent conference call, the CEO expressed disappointment regarding the hazard ratio, which did not meet expectations, resulting in an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [3].

Core Viewpoint - The conference call discusses the top line results of the Phase III INDIGO trial for obexelimab, aimed at treating immunoglobulin G4-related disease (IgG4-RD) [2]. Group 1: Company Overview - Zenas Biopharma is conducting a registrational Phase III trial for obexelimab, which targets IgG4-RD [2]. - The call is being recorded and will be available for replay on the company's website [1]. Group 2: Forward-Looking Statements - The presentation includes forward-looking statements regarding expectations or predictions of future events and performance [3]. - These statements are subject to risks and uncertainties that may lead to actual results differing from those anticipated [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zenas BioPharma, Inc. following a significant drop in stock price after the announcement of Phase 3 trial results for obexelimab [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is currently under investigation for possible securities fraud [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Financial Impact - Following the announcement of the trial results, Zenas's stock price decreased by $17.89 per share, representing a decline of 51.86%, closing at $16.61 per share on January 5, 2026 [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Insights - Zenas BioPharma's phase III INDIGO study for obexelimab in treating IgG4-related disease has met its primary endpoint, showing a significant reduction in flare risk [1][2][7] Study Results - Obexelimab demonstrated a 56% reduction in the risk of IgG4-RD flare compared to placebo over a 52-week period, achieving the primary endpoint of the INDIGO study [2][7] - The treatment also showed significant efficacy across four key secondary endpoints, including reductions in investigator-assessed flares and the number of flares requiring rescue therapy [3][7] Market Reaction - Despite the positive study results, Zenas BioPharma's shares fell by 51.9% on January 5, indicating that the efficacy data may not have met investor expectations [4][7] Future Plans - The company plans to submit a biologics license application to the FDA for obexelimab in Q2 2026 and a marketing authorization application to the European Medicines Agency in the second half of 2026 [5][7] Ongoing Development - Zenas BioPharma is also exploring obexelimab for other autoimmune diseases, with ongoing studies for systemic lupus erythematosus and multiple sclerosis [8][9] - The company is focused on the successful development of obexelimab and other pipeline candidates, as it currently lacks a marketed product [10] Stock Performance - Over the past six months, Zenas BioPharma's shares have increased by 69.7%, outperforming the industry average rise of 21.5% [6]

Market Overview - U.S. stock futures showed mixed results, with Dow futures declining by 0.2% [1] Company-Specific Movements - Jefferson Capital Inc (NASDAQ:JCAP) experienced a significant drop of 4.4%, trading at $22.00, following the announcement of a secondary offering of 10 million shares [1] - MOBIX LABS, INC. (NASDAQ:MOBX) fell sharply by 25.4% to $0.24 due to plans for a common stock offering [2] - Datavault AI Inc (NASDAQ:DVLT) shares decreased by 12.4% to $1.26 after a previous surge of 43% on Monday, linked to a nationwide deployment announcement [2] - BitVentures Ltd – ADR (NASDAQ:BVC) saw a decline of 9.7% to $13.33 after a 5% gain on Monday [2] - Zenas Biopharma Inc (NASDAQ:ZBIO) tumbled by 6.6% to $15.50 following a 52% drop on Monday due to Phase 3 trial results [2] - Theravance Biopharma Inc (NASDAQ:TBPH) dipped 6% to $17.07 after a 3% decline on Friday [2] - Graphic Packaging Holding Co (NYSE:GPK) fell 4.9% to $14.70 ahead of its fourth quarter financial results announcement [2] - ATRenew Inc (NYSE:RERE) declined by 4.1% to $5.65 after a 9% gain on Monday [2] - Rezolve AI PLC (NASDAQ:RZLV) fell 3.7% to $3.07 in pre-market trading [2] - NovaBay Pharmaceuticals Inc (NYSE:NBY) slipped 3.4% to $6.52 after a 15% jump on Monday [2] - Starfighters Space Inc (NYSE:FJET) decreased by 3.3% to $9.08 after a 10% dip on Monday [2]

Core Viewpoint - Zenas BioPharma's shares dropped over 50% following the Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease, as efficacy metrics did not meet market expectations, leading to a significant stock repricing [1][2]. Group 1: Trial Results and Market Reaction - The Phase 3 trial showed a meaningful reduction in flare risk, but the overall efficacy metrics fell short of what the market anticipated, resulting in a sharp decline in stock price [1][2]. - The stock's cyclical positioning indicated elevated risk prior to the trial results, which explains the aggressive selloff [2]. Group 2: Adhishthana Framework Analysis - Zenas BioPharma is currently in Phase 2 of its 18-phase Adhishthana cycle, which is characterized by two segments: the Sankhya period (consolidation and volatility) and the Buddhi period (sustained upside moves) [3]. - The stock's initial rally during the Sankhya period was atypical, as premature rallies in this phase are often unstable and corrected quickly [4][6]. Group 3: Future Outlook and Investment Strategy - Despite the significant decline, caution is advised as Zenas remains in the Sankhya period, with high volatility expected until a transition to the Buddhi phase occurs [7][12]. - Deviations during Phase 2 can impair the quality of any subsequent Buddhi move, suggesting that anticipated rallies may not materialize, supporting a wait-and-watch approach [8][9]. - The recent downgrade from Morgan Stanley aligns with the deteriorating risk profile of the stock, indicating latent structural risks not immediately visible through fundamentals [9][10].

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2].

Core Insights - The analysis highlights significant price declines among three companies, emphasizing the volatility in the biotech and technology sectors [1][4][5] Company Summaries Zenas BioPharma Inc. (NASDAQ:ZBIO) - Experienced a -57.30% drop in stock price, falling to $14.73, following the Phase 3 INDIGO trial results for obexelimab despite positive outcomes [1][5] - The market's negative reaction indicates the unpredictable nature of biotech investments [5] Signing Day Sports, Inc. (SGN) - Stock price decreased to $0.51, reflecting a -46.30% change [2] - The company announced an opportunity in AI and HPC infrastructure with BlockchAIn Digital Infrastructure, but competitive pressures and operational challenges may have contributed to the decline [2] Shineco, Inc. (SISI) - Experienced a -37.16% drop, with stock price falling to $0.18 [3] - The company saw a 6.8% decline during mid-day trading, despite a 99% reduction in trading volume, suggesting market competition and regulatory challenges in China's sectors may be impacting its performance [3] Market Trends - The significant price movements among these companies underscore the stock market's volatility, particularly in the biotech and technology sectors [4] - Investors must consider clinical trial outcomes, regulatory decisions, and competitive pressures when making informed decisions in this rapidly changing landscape [4]

Market Performance - U.S. stocks experienced gains, with the Dow Jones index increasing by 1.66% to 49,183.51, the NASDAQ rising by 0.80% to 23,420.85, and the S&P 500 up by 0.81% to 6,913.76 [1] - European shares also saw positive movement, with the eurozone's STOXX 600 gaining 0.94%, Spain's IBEX 35 Index rising by 0.70%, London's FTSE 100 up by 0.54%, Germany's DAX increasing by 1.34%, and France's CAC 40 climbing by 0.20% [5] - Asian markets closed mostly higher, highlighted by Japan's Nikkei 225 gaining 2.97% and China's Shanghai Composite surging 1.38%, while India's BSE Sensex fell by 0.38% [6] Commodity Prices - In commodity trading, oil prices increased by 1.7% to $58.30, gold rose by 2.9% to $4,454.40, silver surged by 7.3% to $76.230, and copper climbed by 5.1% to $5.9815 [4] Company Developments - Momentus Inc (NASDAQ:MNTS) shares surged by 57% to $8.98 following the announcement of an additive-manufactured fuel tank for flight testing [8] - GH Research PLC (NASDAQ:GHRS) shares increased by 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application for GH001 [8] - VerifyMe Inc (NASDAQ:VRME) shares rose by 66% to $1.12 due to a strategic merger letter of intent with Open World [8] - Zenas Biopharma Inc (NASDAQ:ZBIO) shares dropped by 57% to $14.94 after announcing results from the Phase 3 INDIGO trial [8] - Palisade Bio Inc (NASDAQ:PALI) shares fell by 16% to $2.10, and Palvella Therapeutics Inc (NASDAQ:PVLA) decreased by 14% to $86.16 [8] Economic Indicators - The ISM manufacturing PMI declined for the third consecutive month to 47.9 in December, marking the lowest reading since October 2024, down from 48.2 in November and below market estimates of 48.3 [2][7]